Clinical trial
GVAX® Vaccine for Prostate Cancer vs Docetaxel & Prednisone in Patients With…
NCT00089856 · Cell Genesys, Industry · Terminated
Key facts
| NCT number | NCT00089856 |
|---|---|
| Title | GVAX® Vaccine for Prostate Cancer vs Docetaxel & Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer |
| Official title | A Phase III Randomized, Open-Label Study of CG1940 and CG8711 Versus Docetaxel and Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer Who Are Chemotherapy-Naïve |
| Lead sponsor | Cell Genesys, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Biological, Drug |
| Interventions | Immunotherapy with allogeneic prostate vaccine, Chemotherapy (Taxotere and prednisone) |
| Enrollment | 626 |
| Start date | Jul 1, 2004 |
| Primary completion | Oct 1, 2008 |
| Completion | Oct 1, 2008 |
| First posted | Aug 18, 2004 |
| Last update posted | Nov 5, 2008 |
| Countries | Belgium, Canada, France, Germany, Netherlands, Sweden, United Kingdom, United States |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: